Park Yejong, Hwang Dae Wook, Lee Jae Hoon, Song Ki Byung, Jun Eunsung, Lee Woohyung, Sung Minkyu, Kim Song Cheol
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Gyeonggi-do, Republic of Korea.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea.
Surg Endosc. 2025 Sep 18. doi: 10.1007/s00464-025-12234-x.
Minimally invasive distal pancreatectomy (MIDP) is favored for left-sided pancreatic tumors, but its safety and feasibility in patients with prior upper abdominal surgery (PUAS), especially major PUAS, remain uncertain.
This retrospective cohort study analyzed 1713 patients undergoing MIDP at a single tertiary center from 2009 to 2020. Patients were divided into three groups: those with no prior abdominal surgery (no-PAS, n = 1612), those with minor PUAS (n = 58), and those with major PUAS (n = 43). Primary and secondary endpoints included complications of Clavien-Dindo grade III or higher, conversion to open surgery, length of hospital stay, 90-day mortality, and readmission rates.
Among the 1713 patients who underwent MIDP, no significant differences in the rate of severe complications (Clavien-Dindo grade III or higher) were observed between the no-PAS group (9.4%) and either the minor-PUAS (10.3%, p = 0.991) or major-PUAS (7.0%, p = 0.792) groups. Conversion to open surgery occurred in 3.5% of patients in the no-PAS group, with slightly higher rates in the minor-PUAS (5.2%, p = 0.266) and major-PUAS (7.0%, p = 0.202) groups; however, these differences were not statistically significant. Length of hospital stay, 90-day mortality, and readmission rates were comparable across groups.
MIDP appears to be a safe and feasible option for selected patients with PUAS, including major procedures, without significantly increasing the risks of severe complications or conversion to open surgery. These findings support the broader use of MIDP in patients with complex surgical histories.
微创远端胰腺切除术(MIDP)适用于左侧胰腺肿瘤,但对于既往有上腹部手术史(PUAS)的患者,尤其是大型PUAS患者,其安全性和可行性仍不确定。
这项回顾性队列研究分析了2009年至2020年在单一三级中心接受MIDP的1713例患者。患者分为三组:无既往腹部手术史的患者(无PAS,n = 1612)、小型PUAS患者(n = 58)和大型PUAS患者(n = 43)。主要和次要终点包括Clavien-Dindo III级或更高等级的并发症、转为开放手术、住院时间、90天死亡率和再入院率。
在接受MIDP的1713例患者中,无PAS组(9.4%)与小型PUAS组(10.3%,p = 0.991)或大型PUAS组(7.0%,p = 0.792)之间在严重并发症(Clavien-Dindo III级或更高等级)发生率上未观察到显著差异。无PAS组3.5%的患者转为开放手术,小型PUAS组(5.2%,p = 0.266)和大型PUAS组(7.0%,p = 0.202)的发生率略高;然而,这些差异无统计学意义。各组之间的住院时间、90天死亡率和再入院率相当。
对于选定的PUAS患者,包括大型手术患者,MIDP似乎是一种安全可行的选择,不会显著增加严重并发症或转为开放手术的风险。这些发现支持在有复杂手术史的患者中更广泛地使用MIDP。